GT200100037A - THE 5-ALQUILPIRIDO (2,3-D) PYRIMIDINS ARE INHIBITORS OF THYROSINE KINES AND DEPENDS ON THE CYCLINE. - Google Patents

THE 5-ALQUILPIRIDO (2,3-D) PYRIMIDINS ARE INHIBITORS OF THYROSINE KINES AND DEPENDS ON THE CYCLINE.

Info

Publication number
GT200100037A
GT200100037A GT200100037A GT200100037A GT200100037A GT 200100037 A GT200100037 A GT 200100037A GT 200100037 A GT200100037 A GT 200100037A GT 200100037 A GT200100037 A GT 200100037A GT 200100037 A GT200100037 A GT 200100037A
Authority
GT
Guatemala
Prior art keywords
cycline
inhibitors
depends
alquilpirido
pyrimidins
Prior art date
Application number
GT200100037A
Other languages
Spanish (es)
Inventor
Booth Richard John
Dobrusin Ellen Myra
Toogood Peter Laurence
Vaderwel Scott Norman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200100037A publication Critical patent/GT200100037A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ESTA INVENCION SE REFIERE A LA 5ALQUILPRIDOPIRIMIDINAS CON INHIBIDORES DE LAS CINASAS QUE DEPENDEN DE LA CICLINA, EN PARTICULAR DE LA CINASA 4 QUE DEPENDE DE LA CICLINA. LOS COMPUESTOS DE LA INVENCION SON UTILES PARA EL TRATAMIENTO DE LA INFLAMACION, LAS ENFERMEDADES PROLIFERATIVAS DE LAS CELULAS COMO EL CANCER Y LA RESTENOSIS, Y LAS ENFERMEDADES NEURODEGENERATIVAS, COMO LA ENFERMEDAD DE ALZHEIMER.THIS INVENTION REFERS TO THE 5ALQUILPRIDOPIRIMIDINAS WITH INHIBITORS OF THE KINASES THAT DEPEND ON THE CYCLINE, IN PARTICULAR OF THE KINASE 4 THAT DEPENDS ON THE CYCLINE. THE COMPOUNDS OF THE INVENTION ARE USEFUL FOR THE TREATMENT OF INFLAMMATION, PROLIFERATIVE DISEASES OF CELLS LIKE CANCER AND RESTENOSIS, AND NEURODEGENERATIVE DISEASES, LIKE ALZHEIMER'S DISEASE.

GT200100037A 2000-03-06 2001-03-05 THE 5-ALQUILPIRIDO (2,3-D) PYRIMIDINS ARE INHIBITORS OF THYROSINE KINES AND DEPENDS ON THE CYCLINE. GT200100037A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06

Publications (1)

Publication Number Publication Date
GT200100037A true GT200100037A (en) 2002-03-04

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200100037A GT200100037A (en) 2000-03-06 2001-03-05 THE 5-ALQUILPIRIDO (2,3-D) PYRIMIDINS ARE INHIBITORS OF THYROSINE KINES AND DEPENDS ON THE CYCLINE.

Country Status (36)

Country Link
EP (1) EP1268476A1 (en)
JP (1) JP2003528101A (en)
KR (1) KR20020075805A (en)
CN (1) CN1422268A (en)
AP (1) AP2002002643A0 (en)
AR (1) AR034119A1 (en)
AU (1) AU2001233028A1 (en)
BG (1) BG107161A (en)
BR (1) BR0109056A (en)
CA (1) CA2401368A1 (en)
CO (1) CO5280200A1 (en)
CR (1) CR6736A (en)
CZ (1) CZ20022929A3 (en)
DZ (1) DZ3308A1 (en)
EA (1) EA200200802A1 (en)
EE (1) EE200200506A (en)
GT (1) GT200100037A (en)
HN (1) HN2001000040A (en)
HR (1) HRP20020798A2 (en)
HU (1) HUP0300136A2 (en)
IL (1) IL151480A0 (en)
IS (1) IS6524A (en)
MA (1) MA26881A1 (en)
MX (1) MXPA02008535A (en)
NO (1) NO20024235L (en)
NZ (1) NZ520962A (en)
OA (1) OA12227A (en)
PA (1) PA8513201A1 (en)
PE (1) PE20011177A1 (en)
PL (1) PL358271A1 (en)
SK (1) SK12472002A3 (en)
SV (1) SV2001000338A (en)
TN (1) TNSN01036A1 (en)
WO (1) WO2001070741A1 (en)
YU (1) YU66502A (en)
ZA (1) ZA200207110B (en)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CZ20031125A3 (en) 2000-10-23 2003-10-15 Smithkline Beecham Corporation Novel compounds
ATE305303T1 (en) * 2001-02-12 2005-10-15 Hoffmann La Roche 6-SUBSTITUTED PYRIDOPYRIMIDINES
EP1364950A4 (en) * 2001-02-26 2005-03-09 Tanabe Seiyaku Co Pyridopyrimidine or naphthyridine derivative
US20030105115A1 (en) * 2001-06-21 2003-06-05 Metcalf Chester A. Novel pyridopyrimidines and uses thereof
US20030100572A1 (en) * 2001-06-21 2003-05-29 Ariad Pharmaceuticals,Inc. Novel pyridopyrimidones and uses thereof
CN101001857B (en) * 2002-01-22 2011-06-22 沃尼尔·朗伯有限责任公司 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
PL373339A1 (en) 2002-04-19 2005-08-22 Smithkline Beecham Corporation Novel compounds
AU2003250701A1 (en) 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
AU2003273675A1 (en) 2002-10-09 2004-05-04 Wayne R. Danter Protein tyrosine kinase inhibitors
DE602004021558D1 (en) * 2003-01-17 2009-07-30 Warner Lambert Co 2-AMINOPYRIDINE SUBSTITUTED HETEROCYCLES AS INHIBITORS OF CELLULAR PROLIFERATION
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US8362017B2 (en) 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
ATE356124T1 (en) 2003-11-13 2007-03-15 Hoffmann La Roche HYDROXYALKYL SUBSTITUTED PYRIDO-7-PYRIMIDINE-7-ONE
DE102004029784A1 (en) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
DE102004033670A1 (en) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pyridodihydropyrazinone, process for its preparation and its use as a medicament
FR2873118B1 (en) 2004-07-15 2007-11-23 Sanofi Synthelabo PYRIDO-PYRIMIDINE DERIVATIVES, THEIR APPLICATION IN THERAPEUTICS
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1630163A1 (en) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, methods for their preparation and their use as drugs
WO2006021547A1 (en) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
DE102004058337A1 (en) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for the preparation of fused piperazin-2-one derivatives
WO2006076706A1 (en) 2005-01-14 2006-07-20 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with raf-kinase inhibitory activity
AR053346A1 (en) 2005-03-25 2007-05-02 Glaxo Group Ltd COMPOSITE DERIVED FROM 8H -PIRIDO (2,3-D) PIRIMIDIN -7 ONA 2,4,8- TRISUSTITUTED PHARMACEUTICAL COMPOSITION AND USE TO PREPARE A COMPOSITION FOR TREATMENT AND PROFILXIS OF A DISEASE MEDIATED BY KINASE CSBP / RK / P38
EA200702073A1 (en) 2005-03-25 2008-12-30 Глэксо Груп Лимитед Method of producing pyrido [2,3-d] pyrimidine-7-bp and 3,4-dihidropyrimido [4,5-d] pyrmidin-2 (1h) -onovy derivatives
UY29439A1 (en) 2005-03-25 2006-10-02 Glaxo Group Ltd NEW COMPOUNDS
JP2008535822A (en) 2005-03-25 2008-09-04 グラクソ グループ リミテッド New compounds
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
FR2887882B1 (en) * 2005-07-01 2007-09-07 Sanofi Aventis Sa PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
TW200800983A (en) 2005-09-14 2008-01-01 Janssen Pharmaceutica Nv 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
WO2007044813A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
WO2007044698A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
FR2896246B1 (en) 2006-01-13 2008-08-15 Sanofi Aventis Sa PYRIDO-PYRIMIDONE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
MX2009002927A (en) 2006-09-15 2009-03-31 Pfizer Prod Inc Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors.
JP2010506902A (en) * 2006-10-16 2010-03-04 ジーピーシー・バイオテック・インコーポレーテッド Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
WO2008055013A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
FR2910813B1 (en) 2006-12-28 2009-02-06 Sanofi Aventis Sa NEW THERAPEUTIC USE FOR THE TREATMENT OF LEUKEMIA
UA101611C2 (en) * 2007-04-03 2013-04-25 Аррей Байофарма Инк. Compounds of imidazo[1,2-a]pyridine as receptor tyrosine kinase inhibitors
EP2168966B1 (en) 2007-06-15 2016-09-28 Msd K.K. Bicycloaniline derivative
CA2695406A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
KR20100095020A (en) 2007-12-19 2010-08-27 암젠 인크 Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
EP2225226B1 (en) 2007-12-26 2016-08-17 Critical Outcome Technologies, Inc. Compounds and their use in a method for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
ATE531372T1 (en) * 2008-04-07 2011-11-15 Amgen Inc GEM-DISUBSTITUTED AND SPIROCYCLIC AMINOPYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
CA2730890C (en) 2008-07-17 2018-05-15 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
AR073524A1 (en) 2008-09-30 2010-11-10 Exelixis Inc PI3K A AND M TOR INHIBITING PYRIDOPIRIMIDINONES
TW201100441A (en) 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
JP2013507395A (en) * 2009-10-09 2013-03-04 アフラクシス・インコーポレイテッド 8-Ethyl-6- (aryl) pyrido [2,3-D] pyrimidin-7 (8H) -one for the treatment of CNS disorders
CA2784749C (en) * 2009-12-18 2017-12-12 E. Premkumar Reddy Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
US8901137B2 (en) 2010-02-09 2014-12-02 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
EP2552915B1 (en) 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Compounds for the treatment of hiv
EA022527B1 (en) * 2010-08-05 2016-01-29 Темпл Юниверсити - Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн 2-SUBSTITUTED-8-ALKYL-7-OXO-7,8-DIHYDROPYRIDO[2,3-d]PYRIMIDINE-6-CARBONITRILES AND USES THEREOF
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
JP6000273B2 (en) 2010-11-29 2016-09-28 オーエスアイ・ファーマシューティカルズ，エルエルシー Macrocyclic kinase inhibitor
PT2688887E (en) 2011-03-23 2015-07-06 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
AU2012255860C1 (en) * 2011-05-17 2015-12-10 Principia Biopharma Inc. Tyrosine kinase inhibitors
EP2817308B1 (en) * 2012-02-23 2016-09-07 AbbVie Inc. Pyridopyrimidinone inhibitors of kinases
PL2958916T3 (en) * 2013-02-21 2019-01-31 Pfizer Inc. Solid forms of a selective cdk4/6 inhibitor
WO2015011236A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
EP3172214B1 (en) 2014-07-26 2020-05-13 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
TWI646094B (en) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
JP6563623B1 (en) 2016-08-15 2019-08-21 ファイザー・インク Pyridopyrimidinone CDK2 / 4/6 inhibitor
EP3589634A4 (en) * 2017-03-03 2020-08-12 Auckland Uniservices Limited Fgfr kinase inhibitors and pharmaceutical uses
AU2019220746A1 (en) 2018-02-15 2020-08-27 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
US20220024916A1 (en) * 2018-12-07 2022-01-27 Hangzhou Innogate Pharma Co., Ltd. Heterocyclic comipound as cdk-hdac dual pathway inhibitor
CN112759589B (en) * 2019-11-01 2022-04-08 暨南大学 Pyrimidopyridinones and their use
WO2021108803A1 (en) 2019-11-26 2021-06-03 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as jak inhibitors
AU2022234998A1 (en) * 2021-03-08 2023-10-12 Jinan University Pyridopyrimidine compounds and applications thereof
WO2024056091A1 (en) * 2022-09-16 2024-03-21 华东师范大学 Pyridonopyrimidine derivative as rsk inhibitor and use thereof
WO2024099403A1 (en) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 Thioether compound having soft drug property and use thereof, and pharmaceutical composition and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
EP0964864B1 (en) * 1997-02-05 2008-04-09 Warner-Lambert Company LLC Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
EP1080092B1 (en) * 1998-05-26 2008-07-23 Warner-Lambert Company LLC Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation

Also Published As

Publication number Publication date
CZ20022929A3 (en) 2003-02-12
HRP20020798A2 (en) 2004-02-29
BR0109056A (en) 2003-06-03
OA12227A (en) 2004-03-18
CN1422268A (en) 2003-06-04
CA2401368A1 (en) 2001-09-27
CO5280200A1 (en) 2003-05-30
ZA200207110B (en) 2003-12-04
AP2002002643A0 (en) 2002-12-31
JP2003528101A (en) 2003-09-24
EP1268476A1 (en) 2003-01-02
SK12472002A3 (en) 2003-04-01
EE200200506A (en) 2004-02-16
KR20020075805A (en) 2002-10-05
HUP0300136A2 (en) 2003-05-28
HN2001000040A (en) 2001-09-06
CR6736A (en) 2004-03-10
AU2001233028A1 (en) 2001-10-03
PE20011177A1 (en) 2001-11-23
MXPA02008535A (en) 2002-12-13
PA8513201A1 (en) 2003-06-30
SV2001000338A (en) 2001-11-30
EA200200802A1 (en) 2003-02-27
AR034119A1 (en) 2004-02-04
NO20024235L (en) 2002-11-05
BG107161A (en) 2003-06-30
DZ3308A1 (en) 2001-09-27
PL358271A1 (en) 2004-08-09
NO20024235D0 (en) 2002-09-05
MA26881A1 (en) 2004-12-20
YU66502A (en) 2005-09-19
IS6524A (en) 2002-08-23
IL151480A0 (en) 2003-04-10
TNSN01036A1 (en) 2005-11-10
NZ520962A (en) 2003-09-26
WO2001070741A1 (en) 2001-09-27

Similar Documents

Publication Publication Date Title
GT200100037A (en) THE 5-ALQUILPIRIDO (2,3-D) PYRIMIDINS ARE INHIBITORS OF THYROSINE KINES AND DEPENDS ON THE CYCLINE.
SV2004001459A (en) 2- (PIRIDIN-2-ILAMINO) -PIRIDO [2,3-D] PIRIMIDIN-7-ONAS REF. PC20501
CO4340688A1 (en) QUINAZOLINE DERIVATIVES AND PROCEDURES FOR THE USE OF THE SAME, AS AGENTS AGAINST CANCER, IN MAMMALS.
CR8102A (en) DERIVATIVES OF PIRAZOLO-QUINAZOLINA, PROCEDURE FOR PREPARATION AND ITS USE AS QUINASE INHIBITORS
PA8606201A1 (en) PIRROLO DERIVATIVES [3,4-c) PIRAZOL ASSETS AS QUINASE INHIBITORS, PROCESS FOR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
UY27222A1 (en) PIRAZOLOPIRIMIDINAS AS THERAPEUTIC AGENTS
PA8537501A1 (en) NAFTOSTIRILS
ES2174250T3 (en) IRREVERSIBLE INHIBITORS OF THYROSINE KINASES.
SV2003001493A (en) SUBSTITUTED INDAZOLS, COMPOSITIONS THAT CONTAIN THEM, MANUFACTURING AND USE PROCEDURE
UY29796A1 (en) NEW COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL, PSYCHIATRIC OR PAIN DISORDERS
AR045179A1 (en) USE OF A COMBINATION OF AN INHIBITOR OF THE KINASA OF THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR AND OF CYTOTOXIC AGENTS FOR THE TREATMENT AND INHIBITION OF CANCER
SV1999000016A (en) DERIVATIVES OF 2- (PURIN-9-IL-TETRAHIDROFURAN-3,4-DIOL REF. PG3443 / SV
ECSP034774A (en) PIRAZOLOPIRIMMIDINAS AS THERAPEUTIC AGENTS
DK1689724T3 (en) Quinazolinone compounds as anticancer agents
BRPI0207961B8 (en) use of epothilone and capecitabine analogues to manufacture medicine to treat solid cancerous tumors and kit comprising said compounds.
CR10370A (en) SUBSTITUTED DERIVATIVES OF PIRROLO-PIRAZOL INHIBITORS OF QUINASA (DIVISIONAL EXP. 7880)
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
CO5271715A1 (en) 7-AZA-INDOLIN-2-WAVES SUBSTITUTED IN 4 AND ITS USE AS PROTEIUNA QUINASA INHIBITORS
SV2002000602A (en) PHARMACEUTICAL COMPOUNDS REF.PCS10 398AJER / BB
PA8598801A1 (en) SALTS OF POLY (ADP-RIBOSA) POLYMERASES TRICICLIC INHIBITORS
PA8622801A1 (en) DERIVATIVES 1H-TIENO (2,3-C) PIRAZOL USEFUL AS QUINASE INHIBITORS
AR032293A1 (en) PHARMACEUTICAL CASE
AR012626A1 (en) A PHARMACEUTICAL COMPOSITION COMPRISING A DERIVATIVE OR ANALOGUE OF LEPTIN AS AN INHIBITOR OF THE PROLIFERATION OF TUMOR CELLS AND THE USE OF SUCH PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF MEDICINE FOR THE TREATMENT OF TUMORS
PT1325011E (en) METHODS AND COMPOUNDS FOR TREATMENT OF PROLIFERATIVE DISEASES
CY1110666T1 (en) PYRAZOLOPYRIMIDINES SUITABLE FOR CANCER DISEASE TREATMENT